Lantheus Holdings, Inc. $LNTH Shares Purchased by GAM Holding AG

GAM Holding AG grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 57.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 12,423 shares of the medical equipment provider’s stock after acquiring an additional 4,541 shares during the period. GAM Holding AG’s holdings in Lantheus were worth $1,017,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Signaturefd LLC grew its stake in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 116 shares in the last quarter. Quarry LP grew its position in Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 470 shares in the last quarter. Hughes Financial Services LLC acquired a new position in Lantheus in the 1st quarter valued at about $81,000. GAMMA Investing LLC grew its holdings in shares of Lantheus by 29.3% in the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock valued at $128,000 after purchasing an additional 298 shares in the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of Lantheus by 252.5% in the first quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock valued at $161,000 after purchasing an additional 1,184 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of LNTH stock opened at $57.69 on Friday. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. The firm has a fifty day moving average price of $54.14 and a 200 day moving average price of $70.31. The company has a market cap of $3.92 billion, a P/E ratio of 15.34 and a beta of 0.09. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $118.21.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The firm had revenue of $92.51 million during the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. Sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,812,000 shares of company stock valued at $382,427,380 over the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on LNTH shares. Weiss Ratings cut shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. William Blair restated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. TD Cowen lowered their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, September 15th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. Finally, JMP Securities lowered their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $74.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.